Aurinia publishes corporate presentation on LUPKYNIS growth strategy in lupus nephritis

• Aurinia Pharmaceuticals outlined continued commercial growth plans for lupus nephritis drug LUPKYNIS, positioning it as only FDA-approved calcineurin inhibitor for the indication.
• For three months ended March 31, 2026, total revenue was $77.7 million, net product sales were $73.6 million, net income was $34.4 million.
• Operating cash flow was $32.6 million for the quarter, versus $1.3 million a year earlier.
• 2026 guidance set total revenue at $315 million to $325 million, net product sales at $305 million to $315 million.
• Pipeline update highlighted aritinercept, a dual BAFF/APRIL inhibitor, as development focus for potential autoimmune disease treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.